Literature DB >> 11599334

The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

H Kalant1.   

Abstract

"Ecstasy" (MDMA) and related drugs are amphetamine derivatives that also have some of the pharmacological properties of mescaline. They have become popular with participants in "raves," because they enhance energy, endurance, sociability and sexual arousal. This vogue among teenagers and young adults, together with the widespread belief that "ecstasy" is a safe drug, has led to a thriving illicit traffic in it. But these drugs also have serious toxic effects, both acute and chronic, that resemble those previously seen with other amphetamines and are caused by an excess of the same sympathomimetic actions for which the drugs are valued by the users. Neurotoxicity to the serotonergic system in the brain can also cause permanent physical and psychiatric problems. A detailed review of the literature has revealed over 87 "ecstasy"-related fatalities, caused by hyperpyrexia, rhabdomyolysis, intravascular coagulopathy, hepatic necrosis, cardiac arrhythmias, cerebrovascular accidents, and drug-related accidents or suicide. The toxic or even fatal dose range overlaps the range of recreational dosage. The available evidence does not yet permit an accurate assessment of the size of the problem presented by the use of these drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11599334      PMCID: PMC81503     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  185 in total

1.  Bilateral gluteal compartment syndrome after 'ecstasy' hyperpyrexia.

Authors:  R Ferrie; R C Loveland
Journal:  J R Soc Med       Date:  2000-05       Impact factor: 5.344

2.  Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users.

Authors:  A C Parrott; E Sisk; J J Turner
Journal:  Drug Alcohol Depend       Date:  2000-07-01       Impact factor: 4.492

3.  3,4-methylenedioxyamphetamine overdose.

Authors:  T Lukaszewski
Journal:  Clin Toxicol       Date:  1979       Impact factor: 4.467

4.  The complications of 'ecstasy' (MDMA)

Authors:  K Verebey; J Alrazi; J H Jaffe
Journal:  JAMA       Date:  1988-03-18       Impact factor: 56.272

Review 5.  Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens.

Authors:  D E Nichols
Journal:  J Psychoactive Drugs       Date:  1986 Oct-Dec

6.  Hyponatraemia after ingestion of ecstasy.

Authors:  B Kessel
Journal:  BMJ       Date:  1994-02-05

7.  Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

Authors:  M Mas; M Farré; R de la Torre; P N Roset; J Ortuño; J Segura; J Camí
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

8.  Stereochemistry of the metabolism of MDMA to MDA.

Authors:  R L Fitzgerald; R V Blanke; J A Rosecrans; R A Glennon
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

9.  Ecstasy induced hepatitis mimicking viral hepatitis.

Authors:  R S Dykhuizen; P W Brunt; P Atkinson; J G Simpson; C C Smith
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

10.  Rhabdomyolysis and shock after intravenous amphetamine administration.

Authors:  W C Kendrick; A R Hull; J P Knochel
Journal:  Ann Intern Med       Date:  1977-04       Impact factor: 25.391

View more
  104 in total

1.  Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.

Authors:  A C Parrott; T Buchanan; T M Heffernan; A Scholey; J Ling; J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

Review 2.  Street drug abuse leading to critical illness.

Authors:  Babak Mokhlesi; Prasad S Garimella; Aaron Joffe; Valerie Velho
Journal:  Intensive Care Med       Date:  2004-03-04       Impact factor: 17.440

3.  Reduced 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-initiated oxidative DNA damage and neurodegeneration in prostaglandin H synthase-1 knockout mice.

Authors:  Winnie Jeng; Peter G Wells
Journal:  ACS Chem Neurosci       Date:  2010-02-23       Impact factor: 4.418

4.  Ecstasy (MDMA) Alters Cardiac Gene Expression and DNA Methylation: Implications for Circadian Rhythm Dysfunction in the Heart.

Authors:  Christopher A Koczor; Ivan Ludlow; Robert S Hight; Zhe Jiao; Earl Fields; Tomika Ludaway; Rodney Russ; Rebecca A Torres; William Lewis
Journal:  Toxicol Sci       Date:  2015-08-06       Impact factor: 4.849

5.  Methylphenidate-induced autoimmune hepatitis.

Authors:  Jason J Lewis; Julia C Iezzoni; Carl L Berg
Journal:  Dig Dis Sci       Date:  2007-01-12       Impact factor: 3.199

6.  MDMA (Ecstasy) use and psychiatric problems.

Authors:  Casey R Guillot; Mitchell E Berman
Journal:  Psychopharmacology (Berl)       Date:  2006-10-24       Impact factor: 4.530

7.  Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences.

Authors:  Melanie Mueller; Amy K Goodwin; Nancy A Ator; Una D McCann; George A Ricaurte
Journal:  J Pharmacol Exp Ther       Date:  2011-04-14       Impact factor: 4.030

8.  Medical conditions of adolescents in alcohol and drug treatment: comparison with matched controls.

Authors:  Jennifer R Mertens; Alan J Flisher; Michael F Fleming; Constance M Weisner
Journal:  J Adolesc Health       Date:  2006-11-29       Impact factor: 5.012

9.  Signal-averaged electrocardiogram in physically healthy, chronic 3,4-methylenedioxymethamphetamine (MDMA) users.

Authors:  Praveen Kanneganti; Marilyn A Huestis; Erin A Kolbrich; Robert Goodwin; Roy C Ziegelstein; David A Gorelick
Journal:  Am J Drug Alcohol Abuse       Date:  2008       Impact factor: 3.829

10.  Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.

Authors:  M Farré; R de la Torre; B O Mathúna; P N Roset; A M Peiró; M Torrens; J Ortuño; M Pujadas; J Camí
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.